MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. It develops programs such as THIO, an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity, and the Second-Generation pipeline of potential telomere-targeting agents.